JAK inhibitors are a relatively novel class of drugs in IBD, including tofacitinib (a pan-JAK inhibitor, predominantly inhibiting JAK1/JAK3), filgotinib (a JAK1 inhibitor), and upadacitinib (a JAK1 inhibitor). The gene discussed is JAK1; the disease is inflammatory bowel disease.